Replies to post #99085 on Biotech Values

[DewDiligence]

Kaletra is such a dog it can't be salvaged.

Your opinion does not appear to be congruent with the consensus of practicing physicians. As you can see from the table in #msg-52408979, Kaletra and Reyataz are almost even in global sales at $1.4B and are miles ahead of the third-biggest PI, Prezista.